Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response.
bladder cancer
immunity
immunomodulation
immunotherapy
microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
09
2019
accepted:
31
01
2020
entrez:
6
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
epublish
Résumé
It is now well-recognized that the tumor microenvironment (TME) is not only a key regulator of cancer progression but also plays a crucial role in cancer treatment responses. Recently, several high-profile publications have demonstrated the importance of particular immune parameters and cell types that dictate responsiveness to immunotherapies. With this increased understanding of TME-mediated therapy, approaches that increase therapeutic efficacy by remodeling the TME are actively being pursued. A classic example of this, in practice by urologists for over 40 years, is the manipulation of the bladder microenvironment for the treatment of non-muscle invasive bladder cancer (NMIBC) by instillation of intravesical bacillus Calmette-Guerin (BCG). The success of BCG treatment is thought to be due to its ability to induce a massive influx of Th1-polarized inflammatory cells, production of Th1 inflammatory cytokines and the generation of tumor-targeted Th1-mediated cytotoxic responses. Whilst BCG immunotherapy is currently the best treatment for NMIBC, ~30% of patients show no response to this treatment. Here we present a review highlighting a variety of promising alternative immunotherapies being developed that remodel the bladder tumor microenvironment. These include (1) the use of oncolytic viruses which selectively replicate within cancer cells whilst also modifying the immunological components of the TME, (2) manipulation of the bladder microbiome to augment the response to BCG or other immunotherapies (3) utilizing Toll-like Receptor agonists as anti-tumor agents due to their potent stimulation of innate and adaptive immunity and (4) the growing recognition that immunotherapeutic strategies that will have the largest impact on patients may require multiple therapeutic approaches combined together. The accumulating knowledge on TME remodeling holds promise for providing an alternative therapy for patients with BCG-unresponsive NMIBC.
Identifiants
pubmed: 32133299
doi: 10.3389/fonc.2020.00175
pmc: PMC7040074
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
175Informations de copyright
Copyright © 2020 Annels, Simpson and Pandha.
Références
PLoS One. 2017 Sep 20;12(9):e0184841
pubmed: 28931051
Am J Clin Exp Urol. 2014 Apr 15;2(1):57-61
pubmed: 25126590
Clin Cancer Res. 2019 Oct 1;25(19):5818-5831
pubmed: 31273010
Clin Cancer Res. 2006 Jan 1;12(1):305-13
pubmed: 16397056
BMJ Open. 2019 Jul 17;9(7):e028287
pubmed: 31320352
Front Immunol. 2015 Jun 08;6:284
pubmed: 26106390
Urol Oncol. 2014 Jan;32(1):45.e23-30
pubmed: 24055426
Oncoimmunology. 2015 May 22;4(7):e1016697
pubmed: 26140240
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
Oncotarget. 2016 Jun 28;7(26):39916-39930
pubmed: 27221038
Urol Oncol. 2014 May;32(4):449-57
pubmed: 24252833
Infect Immun. 2008 Sep;76(9):4163-75
pubmed: 18625732
BMC Microbiol. 2011 Nov 02;11:244
pubmed: 22047020
Oncoimmunology. 2016 Dec 7;6(1):e1265720
pubmed: 28197393
Infect Immun. 2003 Sep;71(9):4873-82
pubmed: 12933828
J Urol. 2009 Apr;181(4):1894-900
pubmed: 19237175
Genes Dis. 2018 May 17;5(3):194-203
pubmed: 30320184
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Gene Ther. 2013 Jan;20(1):7-15
pubmed: 22170342
J Clin Invest. 2017 Aug 1;127(8):2916-2929
pubmed: 28650339
J Immunol. 2007 Jul 1;179(1):31-5
pubmed: 17579017
Clin Exp Immunol. 2012 Sep;169(3):213-9
pubmed: 22861360
Urol Oncol. 2017 Feb;35(2):39.e1-39.e7
pubmed: 28341495
PLoS One. 2012;7(3):e32542
pubmed: 22396773
J Urol. 2012 Dec;188(6):2391-7
pubmed: 23088985
Carcinogenesis. 2015 Oct;36(10):1085-93
pubmed: 26354776
Clin Immunol. 2018 Aug;193:60-69
pubmed: 29410331
Cancer Immunol Res. 2016 Jan;4(1):49-60
pubmed: 26511282
EBioMedicine. 2018 May;31:17-24
pubmed: 29724655
Reprod Sci. 2013 Jul;20(7):791-6
pubmed: 23202727
Cytokine. 2018 Jul;107:105-112
pubmed: 29452720
Oncotarget. 2016 Mar 29;7(13):16130-45
pubmed: 26910920
J Immunother. 2019 Nov/Dec;42(9):354-358
pubmed: 31107371
J Urol. 2004 Oct;172(4 Pt 1):1490-5
pubmed: 15371877
Clin Transl Oncol. 2019 Apr;21(4):391-403
pubmed: 30291519
J Transl Med. 2019 Jan 17;17(1):29
pubmed: 30654801
Nat Rev Cancer. 2009 Jan;9(1):57-63
pubmed: 19052556
Cancer Gene Ther. 2016 Apr;23(4):107-13
pubmed: 26987291
Oncol Rep. 2007 Jun;17(6):1469-74
pubmed: 17487406
Mol Ther Oncolytics. 2019 Apr 25;13:93-106
pubmed: 31080879
Int J Cancer. 2015 Mar 1;136(5):E313-25
pubmed: 25208916
Clin Genitourin Cancer. 2015 Jun;13(3):204-9.e2
pubmed: 25660383
Front Oncol. 2014 Apr 10;4:74
pubmed: 24782985
Sci Rep. 2018 Aug 14;8(1):12157
pubmed: 30108246
Front Cell Infect Microbiol. 2018 May 31;8:167
pubmed: 29904624
PLoS One. 2014 Jun 04;9(6):e96705
pubmed: 24896845
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Urol Oncol. 2018 Oct;36(10):440-447
pubmed: 28755959
Oncol Rep. 2019 Mar;41(3):1863-1874
pubmed: 30628699
J Urol. 2008 Jan;179(1):53-6
pubmed: 17997439
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Nat Rev Cancer. 2017 May;17(5):271-285
pubmed: 28303904
Mol Ther Oncolytics. 2018 Feb 14;9:1-12
pubmed: 29989024
J Immunol. 2001 Aug 15;167(4):1882-5
pubmed: 11489966
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Cell. 2018 Aug 9;174(4):1031-1032
pubmed: 30096300
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Oncoimmunology. 2012 Mar 1;1(2):189-194
pubmed: 22720240
J Virol. 1997 Jun;71(6):4736-43
pubmed: 9151867
Oncoimmunology. 2014 Aug 01;3:e29179
pubmed: 25083332
Clin Cancer Res. 2017 Nov 15;23(22):6771-6780
pubmed: 28855352
Urology. 2019 Apr;126:10-15
pubmed: 30615894
Nature. 2015 Jan 15;517(7534):293-301
pubmed: 25592534
Int J Mol Sci. 2017 Oct 19;18(10):
pubmed: 29048388
Int J Cancer. 2001 Jun 1;92(5):697-702
pubmed: 11340575
Onco Targets Ther. 2018 May 16;11:2891-2899
pubmed: 29844686
Clin Cancer Res. 2017 Dec 1;23(23):7388-7399
pubmed: 28928159
Cancers (Basel). 2011 Jul 29;3(3):3055-72
pubmed: 24212945
Cancer. 2007 Apr 15;109(8):1499-505
pubmed: 17340590